Those participants were genetically tested and clinically evaluated to assess both the association between CYP4F2, ApoE, and CYP2A6 polymorphisms and the susceptibility to cardiovascular disease and the impact of those polymorphisms on the sensitivity and responsiveness of warfarin during the initiation phase of therapy. This evidence concerns the gene CYP4F2 and cardiovascular disorder.